EUVIMEDEUVIMED entdecken
Multizentrische Studie

The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer

Taku Naiki iD, Kiyoshi Takahara iD, Hiromitsu Watanabe, Keita Nakane, Yosuke Sugiyama, Takuya Koie, Ryoichi Shiroki, Hideaki Miyake, Takahiro Yasui

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae155 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Taku Naiki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to compare prognostic outcomes of administering first- or second-generation androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer and to find prognostic indicators.

Methods

This retrospective study included 198 patients with non-metastatic castration-resistant prostate cancer from 14 institutions associated with Tokai Urologic Oncology Research Seminar. Forty-two patients were treated with combined androgen blockade using first-generation inhibitors (bicalutamide or flutamide), and 156 were treated with second-generation inhibitors (abiraterone/enzalutamide or apalutamide/darolutamide) after primary androgen deprivation therapy failure. We compared survival outcomes of combined androgen blockade using first-generation inhibitors and second-generation inhibitor treatments, and analyzed clinicopathological or serum parameters and survival outcome.

Results

Combined androgen blockade and second-generation androgen receptor signaling inhibitor groups demonstrated median progression-free survival of 10.2 (95% confidence interval: 5.5–12.3) and 26.0 (95% confidence interval: 21.9–38.4; P < 0.001) months, respectively. Cut-off levels for clinical biomarkers were targeted to <0.2 ng/ml prostate-specific antigen levels 3 months after treatment initiation for non-metastatic castration-resistant prostate cancer; the patient group that achieved this showed better progression-free survival (median 14.7 months, 95% confidence interval: 10.3–23.9 not achieved, median not applicable, 95% confidence interval: 24.6–not applicable achieved; P < 0.00001). Multivariate analysis revealed significant prognostic factors: second-generation androgen receptor signaling inhibitor as first-line treatment (odds ratio: 5.05, 95% confidence interval: 1.54–16.6) and a high hemoglobin level (odds ratio: 2.92, 95% confidence interval: 1.26–6.76).

Conclusions

Our findings suggested prostate-specific antigen < 0.2 ng/ml after 3 months may be a practical prognostic indicator of survival outcomes in non-metastatic castration-resistant prostate cancer. Patients showing a high hemoglobin level should be intensively treated with second-generation androgen receptor signaling inhibitors rather than combined androgen blockade using first-generation inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesAgedPrognosisMiddle AgedAged, 80 and overNitrilesBenzamidesSignal TransductionPhenylthiohydantoinReceptors, AndrogenTosyl CompoundsFlutamideAnilidesThiohydantoinsAndrostenesProgression-Free SurvivalPyrazoles

Stichwörter der Autor:innen

abiraterone acetateapalutamidedarolutamideenzalutamidenon-metastatic castration-resistant prostate cancer

Substanzen

Androgen Receptor AntagonistsNitrilesBenzamidesPhenylthiohydantoinReceptors, AndrogenAndrogen AntagonistsTosyl CompoundsFlutamideapalutamideenzalutamide

Autor:innen und Institutionen

  • Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Urology, Fujita Medical University, Nagoya, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Gifu University, Gifu, Japan.

ORCID-Profile: Taku Naiki, Kiyoshi Takahara

Zitieren

APA

Naiki, T., Takahara, K., Watanabe, H., Nakane, K., Sugiyama, Y., Koie, T., Shiroki, R., Miyake, H., & Yasui, T. (2025). The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae155

Vancouver

Naiki T, Takahara K, Watanabe H, Nakane K, Sugiyama Y, Koie T, et al. The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae155

BibTeX
@article{Naiki2025,
  author = {Naiki, Taku and Takahara, Kiyoshi and Watanabe, Hiromitsu and Nakane, Keita and Sugiyama, Yosuke and Koie, Takuya and Shiroki, Ryoichi and Miyake, Hideaki and Yasui, Takahiro},
  title = {The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae155}
}
Kostenlos starten →